In environments with systemic failures, like healthcare in Nigeria, a product for a single pain point is ineffective. A successful solution must address interconnected issues like supply chain integrity, user financing, and logistics simultaneously, treating the entire value chain as the product.

Product stickiness in health systems is achieved through deep workflow integration. By embedding a solution into the daily processes of every stakeholder—from medical assistants to billing coordinators—it becomes entrenched and difficult to replace, mirroring the zero-churn model of EMR giant Epic.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

The primary challenge for direct-to-consumer (DTC) AI doctor services is not technology but economics. High customer acquisition costs and churn make a standalone subscription model untenable. Successful AI doctors will likely be a top-of-funnel feature for a larger, integrated healthcare business.

Chronic disease patients face a cascade of interconnected problems: pre-authorizations, pharmacy stockouts, and incomprehensible insurance rules. AI's potential lies in acting as an intelligent agent to navigate this complex, fragmented system on behalf of the patient, reducing waste and improving outcomes.

The primary reason most pharmaceutical AI projects fail to deliver value is not technical limitation but strategic failure. Organizations become obsessed with optimizing algorithms while neglecting the foundational blueprint that connects AI investment to measurable business outcomes and operational readiness.

The core issue preventing a patient-centric system is not a lack of technological capability but a fundamental misalignment of incentives and a deep-seated lack of trust between payers and providers. Until the data exists to change incentives, technological solutions will have limited impact.